title: Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
abstract: Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
authors.affiliation: aResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal bSección de Enfermedades Infecciosas, Servicio de Pediatría, Hospital General Universitario 'Gregorio Marañón', Madrid cUnitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona dServicio de Infecciosas Pediátricas, Hospital Universitario 'Doce de Octubre', Madrid eLaboratorio InmunoBiología Molecular, Hospital General Universitario 'Gregorio Marañón', Instituto de Investigación Sanitaria 'Gregrio Marañón' (IiSGM), Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid fUnidad de Estadística y Bioinformática. Institut de Recerca Vall d'Hebron, Barcelona gUnidad Medicina Interna Pediá[Combining Acute Accent]trica, Hospital Infantil Universitario 'Virgen del Rocío', Seville hUnidad Servicio de Pediatría, Hospital Universitario Germans Trias i Pujol Badalona iUnidad de Infectología e Inmunodeficiencias, Servicio de Pediatría, Hospital Regional Universitario 'Carlos Haya', Málaga jUnitat d'Infectologia, Servei de Pediatria; Hospital Sant Joan de Déu, Universitat de Barcelona kPediatric Service, Universitat Autónoma de Barcelona, Hospital del Mar, Barcelona lUnidad de Infectología Pediatrica, Hospital de Cruces, Bilbao mServicio de Enfermedades Infecciosas, Hospital Ramón y Cajal nUnit of Viral Infection and Immunity, National Center for Microbiology, Institute of Health Carlos III, Majadahonda. Madrid, Spain.
authors.forename: Claudia
authors.initials: C
authors.lastname: Palladino
authors.forename: María Luisa Navarro
authors.initials: ML
authors.lastname: Gómez
authors.forename: Pere
authors.initials: P
authors.lastname: Soler-Palacín
authors.forename: María Isabel
authors.initials: MI
authors.lastname: González-Tomé
authors.forename: Santiago J
authors.initials: SJ
authors.lastname: De Ory
authors.forename: María
authors.initials: M
authors.lastname: Espiau
authors.forename: Santiago Pérez
authors.initials: SP
authors.lastname: Hoyos
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: León-Leal
authors.forename: María
authors.initials: M
authors.lastname: Méndez
authors.forename: David
authors.initials: D
authors.lastname: Moreno-Pérez
authors.forename: Claudia Fortuny
authors.initials: CF
authors.lastname: Guasch
authors.forename: Antoni Mur
authors.initials: AM
authors.lastname: Sierra
authors.forename: Itziar Pocheville
authors.initials: IP
authors.lastname: Guruceta
authors.forename: Santiago Moreno
authors.initials: SM
authors.lastname: Guillén
authors.forename: Verónica
authors.initials: V
authors.lastname: Briz
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D000077592:Maraviroc; D056687:Off-Label Use; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc